Michael Moye, President and General Manager of Idorsia US, commented: "The fact that the FDA has expedited the approval of ...

Taking prescription sleep medications within 90 days of knee replacement surgery may be linked to dislocations of the ...

Medications that help patients sleep linked to more falls, fractures, and other problems after joint procedures, a study ...

Daridorexant was associated with improvements in both insomnia and comorbid nocturia in adults aged 55 years and older.

Idorsia Ltd (SIX: IDIA) today announced the publication of the Annual Report 2024 – consisting of the Business Report, Governance Report, Compensation Report, Sustainability Report, and ...

Tokyo, Japan and Cambridge, UK, 25 March 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) announces that its partner Tempero Bio, Inc. has initiated a Phase 2 trial of TMP-301, a ...

Idorsia Ltd (SIX: IDIA) today announced that - effective immediately - the US FDA has fully released TRYVIO™ (aprocitentan) from its REMS (Risk Evaluation and Mitigation Strategy) requirement. TRYVIO ...

Department of Chemistry, Indian Institute of Technology Palakkad, Kerala 678 623, India Physical & Chemical Biology Laboratory and Department of Biological Sciences & Engineering, Indian Institute of ...

Daridorexant, Idorsia’s dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic ...

The study, named A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia, is a reminder of the efficacy of Quviviq (daridorexant), in patients with chronic ...